Warp Drive Bio, Inc.
Industry
- Pharmaceuticals
- Biotechnology
- Drug Discovery Technologies
- Molecular Diversity
- Natural Products
- Genomics-Proteomics
- Bioinformatics
- Molecular Diversity
- Drug Discovery Technologies
Latest on Warp Drive Bio, Inc.
Revolution Medicines Inc. continued this year’s biopharmaceutical initial public offering trend by closing well above its IPO price on its first day of trading. In fact, investors have been so intrig
Recent follow-on public offerings (FOPOs) defied the year-to-date decline in biopharmaceutical stock values with FOPOs as large as $325m for Blueprint Medicines Corp. and $320.8m for Zymeworks Inc.
A start-up with ambitions to disrupt the industry's long-standing drug pricing model could be a new threat to big pharma. EQRx has $200m in financing, a big-name leadership team and a mission to devel
Revolution Medicines Inc. has been on a roll during the past year after entering into a partnership with Sanofi to develop its SHP2 inhibitor, buying Warp Drive Bio Inc. to bolster its cancer dru